SplitAug 13, 2026, 05:12 PM
Silexion Therapeutics Completes 1-for-10 Reverse Share Split
AI Summary
Silexion Therapeutics Corp announced the completion of a 1-for-10 reverse share split, effective May 28, 2026, following shareholder approval. The Company's ordinary shares began trading on a post-split adjusted basis on the Nasdaq Capital Market on May 29, 2026. Consequently, Silexion has retroactively adjusted its audited financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the quarter ended March 31, 2026, to reflect the reduced number of shares and increased per-share prices.
Key Highlights
- Silexion Therapeutics completed a 1-for-10 reverse share split on May 28, 2026.
- The reverse share split was approved by shareholders at a meeting reconvened on May 5, 2026.
- Ordinary shares began trading on a post-split adjusted basis on Nasdaq Capital Market on May 29, 2026.
- The Company retroactively adjusted audited financial statements for the year ended December 31, 2025.
- Unaudited interim financial statements for the quarter ended March 31, 2026, were also retroactively adjusted.
- Previous reverse share splits of 1-for-15 (July 2025) and 1-for-9 (November 2024) were also noted.
Price Impact
More from SLXN